Philippe Armand

Philippe Armand

UNVERIFIED PROFILE

Are you Philippe Armand?   Register this Author

Register author
Philippe Armand

Philippe Armand

Publications by authors named "Philippe Armand"

Are you Philippe Armand?   Register this Author

100Publications

4173Reads

19Profile Views

Emergency general surgery procedures in hematopoietic stem cell transplant recipients.

Am J Surg 2019 Nov 28;218(5):972-977. Epub 2019 Feb 28.

Brigham and Women's Hospital, Division of Trauma, Burn, and Surgical Critical Care, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjsurg.2019.02.030DOI Listing
November 2019

Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.

Hematol Oncol Clin North Am 2019 Aug 18;33(4):575-585. Epub 2019 May 18.

Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2019.03.001DOI Listing
August 2019

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma.

Biol Blood Marrow Transplant 2019 Aug 5. Epub 2019 Aug 5.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Medical Oncology Division, University of Washington, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.07.041DOI Listing
August 2019

The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders.

Curr Hematol Malig Rep 2019 02;14(1):11-21

Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-0493-yDOI Listing
February 2019

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 01 3;25(1):137-144. Epub 2018 Aug 3.

Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.07.039DOI Listing
January 2019

Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2018 11 11;24(11):2344-2353. Epub 2018 May 11.

Transplantation Research Center, Brigham and Women's Hospital, Boston, Massachusetts; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.05.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230502PMC
November 2018

Immunotherapy in aggressive B-cell lymphomas.

Best Pract Res Clin Haematol 2018 09 23;31(3):299-305. Epub 2018 Jul 23.

Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216926183005
Publisher Site
http://dx.doi.org/10.1016/j.beha.2018.07.015DOI Listing
September 2018

Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.

Cancer Immunol Res 2018 06 5;6(6):630-635. Epub 2018 Apr 5.

Departments of Medical Oncology and Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-17-0715DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984707PMC
June 2018

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

J Clin Oncol 2018 05 27;36(14):1428-1439. Epub 2018 Mar 27.

Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy; John M. Timmerman, University of California Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Winship Cancer Institute, Emory University, Atlanta, GA; Jan Paul De Boer, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands, on behalf of Lunenburg Lymphoma Phase I/II Consortium; John Kuruvilla, University of Toronto and Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, BC Cancer Agency, Vancouver, British Columbia, Canada; Marek Trneny, Charles University, General Hospital in Prague, Prague, Czech Republic; Kazunobu Kato, Anne Sumbul, and Benedetto Farsaci, Bristol-Myers Squibb, Princeton, NJ; and Stephen M. Ansell, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.0793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075855PMC
May 2018

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

J Clin Oncol 2018 04 2;36(10):942-950. Epub 2018 Feb 2.

Margaretha G.M. Roemer, Robert A. Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Philippe Armand, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Geraldine S. Pinkus, Azra H. Ligon, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer, VU University Medical Center; Jan Paul De Boer, Antoni van Leeuwenhoek Hospital, Lunenburg Phase I/II Consortium, Amsterdam, the Netherlands; Stephanie Sasse, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas University, Rozzano, Milan; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; John Timmerman, University of California, Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Emory University, Atlanta, GA; John Kuruvilla, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Kerry J. Savage, British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, British Columbia, Canada; Marek Trneny, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic; Stephen Ansell, Mayo Clinic, Rochester, MN; and Kazunobu Kato, Benedetto Farsaci, and Anne Sumbul, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.3994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877802PMC
April 2018

PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.

Br J Haematol 2018 03 11;180(5):752-755. Epub 2016 Nov 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.14441
Publisher Site
http://dx.doi.org/10.1111/bjh.14441DOI Listing
March 2018

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.

Biol Blood Marrow Transplant 2018 01 13;24(1):78-85. Epub 2017 Oct 13.

Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.10.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743624PMC
January 2018

Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.

Br J Haematol 2018 01 26;180(2):177-188. Epub 2017 Oct 26.

Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14996DOI Listing
January 2018

Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.

J Clin Oncol 2017 Dec 21;35(34):3877-3887. Epub 2017 Sep 21.

Alex F. Herrera, City of Hope National Medical Center, Duarte, CA; and Philippe Armand, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.5281DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707209PMC
December 2017

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.

Blood Adv 2017 Dec 12;1(26):2643-2654. Epub 2017 Dec 12.

Department of Pathology, Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017012534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728646PMC
December 2017

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

J Clin Oncol 2017 Jul 25;35(19):2125-2132. Epub 2017 Apr 25.

Robert Chen, City of Hope National Medical Center, Duarte, CA; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Nathalie A. Johnson, Jewish General Hospital, Montreal, Canada; Pauline Brice, Hôpital Saint-Louis, Paris; Vincent Ribrag, Institut Gustave Roussy, Villejuif, France; John Radford, The University of Manchester and Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; Daniel Molin, Uppsala University, Uppsala, Sweden; Theodoros P. Vassilakopoulos, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece; Akihiro Tomita, Nagoya University Graduate School of Medicine, Nagoya, Japan; Bastian von Tresckow, University Hospital Cologne, Cologne, Germany; Yinghua Zhang, Alejandro D. Ricart, and Arun Balakumaran, Merck, Kenilworth, NJ; Craig H. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1316DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791843PMC
July 2017

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.

J Clin Oncol 2017 May 9;35(14):1598-1605. Epub 2017 Jan 9.

Christopher J. Gibson, R. Coleman Lindsley, Brenton G. Mar, Jiantao Shi, Ann S. Lacasce, Arnold S. Freedman, David C. Fisher, Eric Jacobsen, Philippe Armand, Edwin P. Alyea, John Koreth, Vincent Ho, Robert J. Soiffer, Joseph H. Antin, Jerome Ritz, Sarah Nikiforow, Franziska Michor, and Donna Neuberg, Dana-Farber Cancer Institute; Jiantao Shi and Franziska Michor, Harvard T.H. Chan School of Public Health; Siddhartha Jaiswal, Elizabeth A. Morgan, and Benjamin L. Ebert, Brigham and Women's Hospital, Boston; Benjamin L. Ebert, Broad Institute, Cambridge, MA; Vatche Tchekmedyian, Memorial Sloan Kettering Cancer Center, New York, NY; Alysia Bosworth, Anita Bansal, and Stephen J. Forman, City of Hope National Medical Center, Duarte, CA; and Liton Francisco, Jianbo He, Ravi Bhatia, and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.6712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455707PMC
May 2017

Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.

Curr Hematol Malig Rep 2017 02;12(1):44-50

Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0362-5DOI Listing
February 2017

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

J Clin Oncol 2017 Jan 24;35(1):24-31. Epub 2016 Oct 24.

Alex F. Herrera, Matthew Mei, Lawrence Low, Joo Y. Song, Victoria Bedell, Lithua Budde, Wing C. Chan, Robert Chen, Joyce Murata-Collins, Auayporn P. Nademanee, Raju Pillai, Leslie Popplewell, Tanya Siddiqi, Jasmine Zain, Steven T. Rosen, Larry W. Kwak, Stephen J. Forman, Dennis D. Weisenburger, Young Kim, Amrita Krishnan, Tanya Paris, Tracey Stiller, Joycelynne M. Palmer, City of Hope National Medical Center, Duarte, CA; Haesook T. Kim, Jennifer R. Brown, Matthew S. Davids, Arnold S. Freedman, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Ann S. LaCasce, David M. Weinstock, Scott J. Rodig, Philippe Armand, Dana-Farber Cancer Institute; Gabriel K. Griffin, Reid W. Merryman, Christine Pak, Heather Sun, Brigham and Women's Hospital; German A. Pihan, Beth Israel Deaconess Medical Center; and Aliyah R. Sohani, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455688PMC
January 2017

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

J Clin Oncol 2016 11;34(31):3733-3739

Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Vincent Ribrag and Jean-Marie Michot, Institut Gustave Roussy, Villejuif, France; Pier Luigi Zinzani, Institute of Hematology Seràgnoli, University of Bologna, Bologna, Italy; John Kuruvilla, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Ellen S. Snyder, Alejandro D. Ricart, Arun Balakumaran, and Shelonitda Rose, Merck, Kenilworth, NJ; and Craig H. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.3467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791838PMC
November 2016

An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease.

Biol Blood Marrow Transplant 2016 11 30;22(11):2084-2091. Epub 2016 Aug 30.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.08.020DOI Listing
November 2016

Checkpoint blockade in lymphoma.

Authors:
Philippe Armand

Hematology Am Soc Hematol Educ Program 2015 ;2015:69-73

Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2015.1.69DOI Listing
October 2016

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.

Haematologica 2016 10 27;101(10):1251-1259. Epub 2016 Jun 27.

Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.141176DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046655PMC
October 2016

Donor and recipient sex in allogeneic stem cell transplantation: what really matters.

Haematologica 2016 10 27;101(10):1260-1266. Epub 2016 Jun 27.

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.147645DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046656PMC
October 2016

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.

Biol Blood Marrow Transplant 2016 10 25;22(10):1808-1815. Epub 2016 Jul 25.

Department of Hematology, Instituto de Biomedicina de Sevilla (IBIS)/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.07.006DOI Listing
October 2016

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.

J Clin Oncol 2016 09 6;34(26):3141-9. Epub 2016 Jun 6.

Nilanjan Ghosh, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC; Reem Karmali, Rush University Medical Center; Sonali M. Smith, The University of Chicago, Chicago, IL; Vanderson Rocha, Churchill Hospital, Oxford, United Kingdom; Kwang Woo Ahn, Alyssa DiGilio, and Mehdi Hamadani, Medical College of Wisconsin & Center for International Blood and Marrow Transplant Research; Parameswaran N. Hari and Anita D'Souza, Medical College of Wisconsin; Timothy S. Fenske, Froedtert Memorial Lutheran Hospital, Milwaukee, WI; Veronika Bachanova, University of Minnesota Medical Center, Minneapolis, MN; Ulrike Bacher, University Medicine Goettingen and University Cancer Center Hamburg, Hamburg, Germany; Parastoo Dahi, Memorial Sloan Kettering Cancer Center-Adults, New York, NY; Marcos de Lima, University Hospitals Case Medical Center, Cleveland; Samantha Jaglowski, The Ohio State University Medical Center, Columbus, OH; Siddhartha Ganguly, University of Kansas Medical Center, Kansas City, KS; Mohamed A. Kharfan-Dabaja, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Tim D. Prestidge, Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand; Bipin N. Savani, Vanderbilt University Medical Center, Nashville, TN; Anna M. Sureda, European Group for Blood and Marrow Transplantation and Hospital Duran I Reynals, Barcelona, Spain; Edmund K. Waller, Winship Cancer Institute, Emory University, Atlanta, GA; Alex F. Herrera, City of Hope National Medical Center, Duarte, CA; Philippe Armand, Dana-Farber Cancer Institute, Boston, MA; Rachel B. Salit, Fred Hutchinson Cancer Research Center, Seattle, WA; and Nina D. Wagner-Johnston, Ephraim Fuchs, and Javier Bolaños-Meade, Johns Hopkins University Sidney Kimmel Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.3476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012706PMC
September 2016

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

J Clin Oncol 2016 08 11;34(23):2690-7. Epub 2016 Apr 11.

Margaretha G.M. Roemer, Robert A. Redd, Heather Homer, Courtney F. Connelly, Gordon J. Freeman, Philippe Armand, Bjoern Chapuy, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Azra H. Ligon, Heather H. Sun, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer and Daphne de Jong, VU University Medical Center, Amsterdam, the Netherlands; and Ranjana H. Advani, Yasodha Natkunam, Sarah E. Daadi, and Richard T. Hoppe, Stanford University Medical Center, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.4482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019753PMC
August 2016

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

J Clin Oncol 2016 08 6;34(23):2698-704. Epub 2016 Jun 6.

Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer Institute, Portland, OR; Ahmad Halwani, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Martin Gutierrez, Hackensack University Medical Center, Hackensack; Lili Zhu, Joseph F. Grosso, and M. Brigid Bradley Garelik, Bristol-Myers Squibb, Princeton, NJ; Michael M. Millenson, Fox Chase Cancer Center; Adam D. Cohen and Stephen J. Schuster, University of Pennsylvania, Philadelphia, PA; Daniel Lebovic, University of Michigan, Ann Arbor, MI; Madhav Dhodapkar, Yale Cancer Center, New Haven, CT; Ivan Borrello, Johns Hopkins University School of Medicine, Baltimore, MD; and John Timmerman, University of California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.9789DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019749PMC
August 2016

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

N Engl J Med 2016 Jul;375(2):143-53

From the Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School (M.S.D., H.T.K., P.B., R.L., A.S., A.P.L., M.H., M.S., F.S.H., C.J.W., V.T.H., C. Cutler, J.K., E.P.A., J.H.A., P.A., J.R., R.J.S.), the Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center and Harvard Medical School (D.A.), the Bone Marrow Transplant Program, Massachusetts General Hospital Cancer Center and Harvard Medical School (Y.-B.C.), the Departments of Dermatology (N.R.L.) and Pathology (S.R.G., J.L.H., S.J.R.), Dana-Farber and Brigham and Women's Cancer Center, and the Dana-Farber Cancer Institute, Center for Molecular Oncologic Pathology (M.B., C.W.Z.) - all in Boston; Broad Institute of Massachusetts Institute of Technology and Harvard (P.B., C.J.W.) and Neon Therapeutics (M.S.R.) - both in Cambridge; the Blood and Marrow Transplant Program, University of California, San Diego, Moores Cancer Center, La Jolla (C. Costello, E.D.B.); Colorado Blood Cancer Institute, Denver (P.M.); Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (H.S.); and the Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta (A.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1601202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149459PMC
July 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 07 11;30(1):183. Epub 2016 Jul 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.06.008DOI Listing
July 2016

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.

Biol Blood Marrow Transplant 2016 May 31;22(5):910-8. Epub 2015 Dec 31.

Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.12.024DOI Listing
May 2016

Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.

Blood 2016 05 4;127(20):2489-97. Epub 2016 Mar 4.

Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-12-688895DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874229PMC
May 2016

Pulp Obliteration in a Patient with Sclerodermatous Chronic Graft-versus-Host Disease.

J Endod 2016 Apr 20;42(4):678-80. Epub 2016 Feb 20.

Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.joen.2016.01.009DOI Listing
April 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 04;29(4):574-586

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.03.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177991PMC
April 2016

Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

Biol Blood Marrow Transplant 2016 Mar;22(3 Suppl):S9-S14

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.01.005DOI Listing
March 2016

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.

Blood 2016 Feb 15;127(5):646-57. Epub 2015 Dec 15.

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-10-672345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742552PMC
February 2016

Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

Biol Blood Marrow Transplant 2016 Jan 17;22(1):17-22. Epub 2015 Oct 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.10.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706480PMC
January 2016

Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing.

Exp Hematol Oncol 2015 8;4:30. Epub 2015 Oct 8.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40164-015-0026-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599757PMC
October 2015

Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.

Biol Blood Marrow Transplant 2015 Aug 7;21(8):1418-24. Epub 2015 Apr 7.

Transplantation Biology Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791150023
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2015.04.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506728PMC
August 2015

Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.

Biol Blood Marrow Transplant 2015 May 23;21(5):873-80. Epub 2015 Jan 23.

Department of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.01.019DOI Listing
May 2015

Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation.

Biol Blood Marrow Transplant 2015 May 31;21(5):848-54. Epub 2015 Jan 31.

Division of Clinical Research, Fred Hutchinson Cancer Research Center; Department of Medicine, University of Washington, Seattle, Washington. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.01.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408250PMC
May 2015

Immune checkpoint blockade in hematologic malignancies.

Authors:
Philippe Armand

Blood 2015 May 1;125(22):3393-400. Epub 2015 Apr 1.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/content/early/2015/04/01/blood-2
Web Search
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2015-02-56
Publisher Site
http://dx.doi.org/10.1182/blood-2015-02-567453DOI Listing
May 2015

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

N Engl J Med 2015 Jan 6;372(4):311-9. Epub 2014 Dec 6.

From the Mayo Clinic, Rochester, MN (S.M.A.); Memorial Sloan Kettering Cancer Center (A.M.L., D.C.) and Weill Cornell Medical College (A.M.L.) - both in New York; Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore (I.B.); University of Utah Huntsman Cancer Institute, Salt Lake City (A.H.); Oregon Health and Science University and the Knight Cancer Institute, Portland (E.C.S.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack (M.G.), and Bristol-Myers Squibb, Lawrenceville (L.Z., J.F.G., S.Y.K.) - both in New Jersey; Abramson Cancer Center, University of Pennsylvania (S.J.S.), and Fox Chase Cancer Center (M.M.M.) - both in Philadelphia; Dana-Farber Cancer Institute (G.J.F., B.C., M.A.S., P.A.) Brigham and Women's Hospital (S.J.R., A.H.L.), and Harvard Medical School (G.J.F., B.C., M.A.S., P.A., S.J.R., A.H.L.) - all in Boston; and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles (J.M.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348009PMC
January 2015